Loading…
Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes
Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation. Retrospective descriptive study including 17 patients with a diagnosi...
Saved in:
| Published in: | Revista Española de medicina nuclear e imagen molecular (English ed.) 2024-09, p.500064, Article 500064 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c1568-ae899336a4949041adda21b1eef5b29f7ef372ceb7c7a4c3a74b726ef0ee9d693 |
| container_end_page | |
| container_issue | |
| container_start_page | 500064 |
| container_title | Revista Española de medicina nuclear e imagen molecular (English ed.) |
| container_volume | |
| creator | Tobalina Larrea, I. Cuetos Fernández, J. Mendizabal Abad, A. Montero de la Peña, A. García Hernández, D. Portilla Quatrociocchi, G.H. Jiménez Alonso, M. Menchaca Echevarria, M.C. |
| description | Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.
Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.
Of the 17 patients treated with 32P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32P administered was 116−951 MBq (median: 236 MBq). In 14 patients treated with Phosphorus-32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count |
| doi_str_mv | 10.1016/j.remnie.2024.500064 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3111202110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2253808924000922</els_id><sourcerecordid>3111202110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1568-ae899336a4949041adda21b1eef5b29f7ef372ceb7c7a4c3a74b726ef0ee9d693</originalsourceid><addsrcrecordid>eNp9kdtqFTEUhoMottS-gchceuFsc5pDbgQpaoVCobTXIZOs2OzmMCYzhf0gvq_ZnSpeeRFWwv_9ayX5EXpL8I5g0n_c7zKE6GBHMeW7DmPc8xfolNKOtSMexct_9ifovJR9RfDAMaPda3TCBOOMivEU_bqBMqdY4EOjU5i902px9dyoaJrsykOTbONhfYDgdLNkFYtNOTxBR2m-T6WuvJaW0bkCoJYAcWlcrJrzyoCvVbURflTTIzT6PqdYe4UD-DTn5J2FvEnlEE1OAcob9MoqX-D8uZ6hu69fbi8u26vrb98vPl-1mnT92CoYhWCsV1xwgTlRxihKJgJgu4kKO4BlA9UwDXpQXDM18GmgPVgMIEwv2Bl6v_Wt9_i5QllkcEWD9ypCWotkhJD6w4TgivIN1TmVksHKObug8kESLI-ZyL3cMpHHTOSWSbW9e56wTgHMX9OfBCrwaQOgvvPRQZZFO4gajMugF2mS-_-E35lvo7k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111202110</pqid></control><display><type>article</type><title>Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Tobalina Larrea, I. ; Cuetos Fernández, J. ; Mendizabal Abad, A. ; Montero de la Peña, A. ; García Hernández, D. ; Portilla Quatrociocchi, G.H. ; Jiménez Alonso, M. ; Menchaca Echevarria, M.C.</creator><creatorcontrib>Tobalina Larrea, I. ; Cuetos Fernández, J. ; Mendizabal Abad, A. ; Montero de la Peña, A. ; García Hernández, D. ; Portilla Quatrociocchi, G.H. ; Jiménez Alonso, M. ; Menchaca Echevarria, M.C.</creatorcontrib><description>Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.
Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.
Of the 17 patients treated with 32P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32P administered was 116−951 MBq (median: 236 MBq). In 14 patients treated with Phosphorus-32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count <400.000/mm3 in those diagnosed with Essential Thrombocythemia and a hematocrit <45% in cases of Polycythemia Vera. The median follow-up of patients from the date of the first treatment of Phosphorus-32P until study completion or death was 37 months (range: 5–230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and 1 case of mild thrombocytopenia. No leukemic transformation was identified.
In our experience, treatment with Phosphorus-32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.
Describir nuestra experiencia en el tratamiento con Fósforo-32P de síndromes mieloproliferativos crónicos Philadelphia negativos refractarios o con efectos secundarios al tratamiento habitual; con especial atención a sus complicaciones y al riesgo de transformación leucémica.
Estudio descriptivo retrospectivo incluyendo 17 pacientes con diagnóstico de síndrome mieloproliferativo crónico Philadelphia negativo tratados con Fósforo-32P en nuestro hospital desde enero de 1985 a marzo de 2017. Se han analizado las indicaciones, la respuesta al tratamiento, así como las complicaciones precoces y tardías.
De los 17 pacientes tratados con 32P (11 hombres, 6 mujeres; edad media 79,8 años), 6 pacientes presentaban Policitemia Vera y 11 Trombocitosis Esencial. En 9 de los sujetos se administró una única dosis, el resto requirieron dos o más dosis por inadecuada respuesta hematológica y/o recaída. El rango de dosis total de Fósforo-32P administrada fue de 116−951 MBq (mediana: 236 MBq). En 14 pacientes tratados con Fósforo-32P se consigue respuesta completa o parcial en la hematimetría. En 11 pacientes la respuesta fue completa, establecida como una cifra de plaquetas <400.000/mm3 en aquellos diagnosticados de Trombocitemia Esencial y un hematocrito <45% en los casos de Policitemia Vera. La mediana del seguimiento de los pacientes desde la fecha del primer tratamiento con Fósforo-32P hasta la finalización del estudio o su fallecimiento fue de 37 meses (rango: 5–230 meses). Respecto a las complicaciones precoces, se objetivaron 2 casos de anemia que requirieron transfusión sanguínea y 1 caso trombopenia de grado leve. No se identificó ninguna transformación leucémica.
En nuestra experiencia, el tratamiento con Fósforo-32P ha sido una opción terapéutica útil en los síndromes mieloproliferativos crónicos Philadelphia negativos en pacientes de edad avanzada que mostraban mala tolerancia y/o resistencia al tratamiento de primera línea. No hemos identificado ningún caso de transformación leucémica.</description><identifier>ISSN: 2253-8089</identifier><identifier>EISSN: 2253-8089</identifier><identifier>DOI: 10.1016/j.remnie.2024.500064</identifier><identifier>PMID: 39343298</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Acute leukemia ; Essential thrombocythemia ; Fósforo radioactivo ; Fósforo-32P ; Leucemia aguda ; Myeloproliferative disorders ; Phosphorus-32P ; Policitemia vera ; Polycythemia vera ; Radioactive phosphorus ; Síndromes mieloproliferativos ; Trombocitemia esencial</subject><ispartof>Revista Española de medicina nuclear e imagen molecular (English ed.), 2024-09, p.500064, Article 500064</ispartof><rights>2024 Sociedad Española de Medicina Nuclear e Imagen Molecular</rights><rights>Copyright © 2024 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1568-ae899336a4949041adda21b1eef5b29f7ef372ceb7c7a4c3a74b726ef0ee9d693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39343298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tobalina Larrea, I.</creatorcontrib><creatorcontrib>Cuetos Fernández, J.</creatorcontrib><creatorcontrib>Mendizabal Abad, A.</creatorcontrib><creatorcontrib>Montero de la Peña, A.</creatorcontrib><creatorcontrib>García Hernández, D.</creatorcontrib><creatorcontrib>Portilla Quatrociocchi, G.H.</creatorcontrib><creatorcontrib>Jiménez Alonso, M.</creatorcontrib><creatorcontrib>Menchaca Echevarria, M.C.</creatorcontrib><title>Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes</title><title>Revista Española de medicina nuclear e imagen molecular (English ed.)</title><addtitle>Rev Esp Med Nucl Imagen Mol (Engl Ed)</addtitle><description>Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.
Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.
Of the 17 patients treated with 32P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32P administered was 116−951 MBq (median: 236 MBq). In 14 patients treated with Phosphorus-32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count <400.000/mm3 in those diagnosed with Essential Thrombocythemia and a hematocrit <45% in cases of Polycythemia Vera. The median follow-up of patients from the date of the first treatment of Phosphorus-32P until study completion or death was 37 months (range: 5–230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and 1 case of mild thrombocytopenia. No leukemic transformation was identified.
In our experience, treatment with Phosphorus-32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.
Describir nuestra experiencia en el tratamiento con Fósforo-32P de síndromes mieloproliferativos crónicos Philadelphia negativos refractarios o con efectos secundarios al tratamiento habitual; con especial atención a sus complicaciones y al riesgo de transformación leucémica.
Estudio descriptivo retrospectivo incluyendo 17 pacientes con diagnóstico de síndrome mieloproliferativo crónico Philadelphia negativo tratados con Fósforo-32P en nuestro hospital desde enero de 1985 a marzo de 2017. Se han analizado las indicaciones, la respuesta al tratamiento, así como las complicaciones precoces y tardías.
De los 17 pacientes tratados con 32P (11 hombres, 6 mujeres; edad media 79,8 años), 6 pacientes presentaban Policitemia Vera y 11 Trombocitosis Esencial. En 9 de los sujetos se administró una única dosis, el resto requirieron dos o más dosis por inadecuada respuesta hematológica y/o recaída. El rango de dosis total de Fósforo-32P administrada fue de 116−951 MBq (mediana: 236 MBq). En 14 pacientes tratados con Fósforo-32P se consigue respuesta completa o parcial en la hematimetría. En 11 pacientes la respuesta fue completa, establecida como una cifra de plaquetas <400.000/mm3 en aquellos diagnosticados de Trombocitemia Esencial y un hematocrito <45% en los casos de Policitemia Vera. La mediana del seguimiento de los pacientes desde la fecha del primer tratamiento con Fósforo-32P hasta la finalización del estudio o su fallecimiento fue de 37 meses (rango: 5–230 meses). Respecto a las complicaciones precoces, se objetivaron 2 casos de anemia que requirieron transfusión sanguínea y 1 caso trombopenia de grado leve. No se identificó ninguna transformación leucémica.
En nuestra experiencia, el tratamiento con Fósforo-32P ha sido una opción terapéutica útil en los síndromes mieloproliferativos crónicos Philadelphia negativos en pacientes de edad avanzada que mostraban mala tolerancia y/o resistencia al tratamiento de primera línea. No hemos identificado ningún caso de transformación leucémica.</description><subject>Acute leukemia</subject><subject>Essential thrombocythemia</subject><subject>Fósforo radioactivo</subject><subject>Fósforo-32P</subject><subject>Leucemia aguda</subject><subject>Myeloproliferative disorders</subject><subject>Phosphorus-32P</subject><subject>Policitemia vera</subject><subject>Polycythemia vera</subject><subject>Radioactive phosphorus</subject><subject>Síndromes mieloproliferativos</subject><subject>Trombocitemia esencial</subject><issn>2253-8089</issn><issn>2253-8089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kdtqFTEUhoMottS-gchceuFsc5pDbgQpaoVCobTXIZOs2OzmMCYzhf0gvq_ZnSpeeRFWwv_9ayX5EXpL8I5g0n_c7zKE6GBHMeW7DmPc8xfolNKOtSMexct_9ifovJR9RfDAMaPda3TCBOOMivEU_bqBMqdY4EOjU5i902px9dyoaJrsykOTbONhfYDgdLNkFYtNOTxBR2m-T6WuvJaW0bkCoJYAcWlcrJrzyoCvVbURflTTIzT6PqdYe4UD-DTn5J2FvEnlEE1OAcob9MoqX-D8uZ6hu69fbi8u26vrb98vPl-1mnT92CoYhWCsV1xwgTlRxihKJgJgu4kKO4BlA9UwDXpQXDM18GmgPVgMIEwv2Bl6v_Wt9_i5QllkcEWD9ypCWotkhJD6w4TgivIN1TmVksHKObug8kESLI-ZyL3cMpHHTOSWSbW9e56wTgHMX9OfBCrwaQOgvvPRQZZFO4gajMugF2mS-_-E35lvo7k</recordid><startdate>20240928</startdate><enddate>20240928</enddate><creator>Tobalina Larrea, I.</creator><creator>Cuetos Fernández, J.</creator><creator>Mendizabal Abad, A.</creator><creator>Montero de la Peña, A.</creator><creator>García Hernández, D.</creator><creator>Portilla Quatrociocchi, G.H.</creator><creator>Jiménez Alonso, M.</creator><creator>Menchaca Echevarria, M.C.</creator><general>Elsevier España, S.L.U</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240928</creationdate><title>Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes</title><author>Tobalina Larrea, I. ; Cuetos Fernández, J. ; Mendizabal Abad, A. ; Montero de la Peña, A. ; García Hernández, D. ; Portilla Quatrociocchi, G.H. ; Jiménez Alonso, M. ; Menchaca Echevarria, M.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1568-ae899336a4949041adda21b1eef5b29f7ef372ceb7c7a4c3a74b726ef0ee9d693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute leukemia</topic><topic>Essential thrombocythemia</topic><topic>Fósforo radioactivo</topic><topic>Fósforo-32P</topic><topic>Leucemia aguda</topic><topic>Myeloproliferative disorders</topic><topic>Phosphorus-32P</topic><topic>Policitemia vera</topic><topic>Polycythemia vera</topic><topic>Radioactive phosphorus</topic><topic>Síndromes mieloproliferativos</topic><topic>Trombocitemia esencial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tobalina Larrea, I.</creatorcontrib><creatorcontrib>Cuetos Fernández, J.</creatorcontrib><creatorcontrib>Mendizabal Abad, A.</creatorcontrib><creatorcontrib>Montero de la Peña, A.</creatorcontrib><creatorcontrib>García Hernández, D.</creatorcontrib><creatorcontrib>Portilla Quatrociocchi, G.H.</creatorcontrib><creatorcontrib>Jiménez Alonso, M.</creatorcontrib><creatorcontrib>Menchaca Echevarria, M.C.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista Española de medicina nuclear e imagen molecular (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tobalina Larrea, I.</au><au>Cuetos Fernández, J.</au><au>Mendizabal Abad, A.</au><au>Montero de la Peña, A.</au><au>García Hernández, D.</au><au>Portilla Quatrociocchi, G.H.</au><au>Jiménez Alonso, M.</au><au>Menchaca Echevarria, M.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes</atitle><jtitle>Revista Española de medicina nuclear e imagen molecular (English ed.)</jtitle><addtitle>Rev Esp Med Nucl Imagen Mol (Engl Ed)</addtitle><date>2024-09-28</date><risdate>2024</risdate><spage>500064</spage><pages>500064-</pages><artnum>500064</artnum><issn>2253-8089</issn><eissn>2253-8089</eissn><abstract>Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.
Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.
Of the 17 patients treated with 32P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32P administered was 116−951 MBq (median: 236 MBq). In 14 patients treated with Phosphorus-32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count <400.000/mm3 in those diagnosed with Essential Thrombocythemia and a hematocrit <45% in cases of Polycythemia Vera. The median follow-up of patients from the date of the first treatment of Phosphorus-32P until study completion or death was 37 months (range: 5–230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and 1 case of mild thrombocytopenia. No leukemic transformation was identified.
In our experience, treatment with Phosphorus-32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.
Describir nuestra experiencia en el tratamiento con Fósforo-32P de síndromes mieloproliferativos crónicos Philadelphia negativos refractarios o con efectos secundarios al tratamiento habitual; con especial atención a sus complicaciones y al riesgo de transformación leucémica.
Estudio descriptivo retrospectivo incluyendo 17 pacientes con diagnóstico de síndrome mieloproliferativo crónico Philadelphia negativo tratados con Fósforo-32P en nuestro hospital desde enero de 1985 a marzo de 2017. Se han analizado las indicaciones, la respuesta al tratamiento, así como las complicaciones precoces y tardías.
De los 17 pacientes tratados con 32P (11 hombres, 6 mujeres; edad media 79,8 años), 6 pacientes presentaban Policitemia Vera y 11 Trombocitosis Esencial. En 9 de los sujetos se administró una única dosis, el resto requirieron dos o más dosis por inadecuada respuesta hematológica y/o recaída. El rango de dosis total de Fósforo-32P administrada fue de 116−951 MBq (mediana: 236 MBq). En 14 pacientes tratados con Fósforo-32P se consigue respuesta completa o parcial en la hematimetría. En 11 pacientes la respuesta fue completa, establecida como una cifra de plaquetas <400.000/mm3 en aquellos diagnosticados de Trombocitemia Esencial y un hematocrito <45% en los casos de Policitemia Vera. La mediana del seguimiento de los pacientes desde la fecha del primer tratamiento con Fósforo-32P hasta la finalización del estudio o su fallecimiento fue de 37 meses (rango: 5–230 meses). Respecto a las complicaciones precoces, se objetivaron 2 casos de anemia que requirieron transfusión sanguínea y 1 caso trombopenia de grado leve. No se identificó ninguna transformación leucémica.
En nuestra experiencia, el tratamiento con Fósforo-32P ha sido una opción terapéutica útil en los síndromes mieloproliferativos crónicos Philadelphia negativos en pacientes de edad avanzada que mostraban mala tolerancia y/o resistencia al tratamiento de primera línea. No hemos identificado ningún caso de transformación leucémica.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>39343298</pmid><doi>10.1016/j.remnie.2024.500064</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2253-8089 |
| ispartof | Revista Española de medicina nuclear e imagen molecular (English ed.), 2024-09, p.500064, Article 500064 |
| issn | 2253-8089 2253-8089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3111202110 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Acute leukemia Essential thrombocythemia Fósforo radioactivo Fósforo-32P Leucemia aguda Myeloproliferative disorders Phosphorus-32P Policitemia vera Polycythemia vera Radioactive phosphorus Síndromes mieloproliferativos Trombocitemia esencial |
| title | Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A34%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response,%20complications%20and%20risk%20of%20leukemic%20transformation%20of%20phosphorus-32p%20treatment%20in%20philadelphia-negative%20chronic%20myeloproliferative%20syndromes&rft.jtitle=Revista%20Espa%C3%B1ola%20de%20medicina%20nuclear%20e%20imagen%20molecular%20(English%20ed.)&rft.au=Tobalina%20Larrea,%20I.&rft.date=2024-09-28&rft.spage=500064&rft.pages=500064-&rft.artnum=500064&rft.issn=2253-8089&rft.eissn=2253-8089&rft_id=info:doi/10.1016/j.remnie.2024.500064&rft_dat=%3Cproquest_cross%3E3111202110%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1568-ae899336a4949041adda21b1eef5b29f7ef372ceb7c7a4c3a74b726ef0ee9d693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3111202110&rft_id=info:pmid/39343298&rfr_iscdi=true |